Zydus Lifesciences Limited · NSE:ZYDUSLIFE

Zydus Lifesciences — Cadila Healthcare — Investor Presentation (September 2012)

20 slides from Zydus Lifesciences's investor presentation, September 2012

  1. Slide 1: Cadila Healthcare Limited Investor Presentation

    Cadila Healthcare Limited Investor Presentation September 2012

  2. Slide 2: Well integrated pharma player with global footprints

    Well integrated pharma player with global footprints ~60 years $ 1 bn + >6% of sales Operational Global Revenues Spent on R&D annually experience 20+ mfg. sites ~23% CAGR 300+ products In Sales and Net Registered annually Producing >12 Profits for US, EU, Japan and bn pills annually (FY ‘07 – FY ‘12

  3. Slide 3: History of achieving milestones consistently

    History of achieving milestones consistently 25 fold growth in sales over last 16 years… …with significant external recognition Economic Times Emerging Company of the year 2010 Kaizen Institute - Operational Rs. 200 cr. Excellence in Tablet in 1995 Manufacturing in 2010 3

  4. Slide 4: We have a vision to march Beyond the Billion by 2020

    We have a vision to march Beyond the Billion Zydus shall be a leading global healthcare provider with a robust product pipeline; Stepping beyond the billion, we shall achieve sales of over $3 bn by 2015 and be a research-based pharmaceutical company by 2020… 4

  5. Slide 5: Journey Beyond the Billion (BtB)

    Journey Beyond the Billion (BtB) … Conducted a comprehensive strategy exercise to achieve the vision Corporate strategy, Business specific Implementation Business portfolio mix strategies planning • Opportunity evaluation of • Vision and detailed • Synthesis of business all potential markets strateg

  6. Slide 6: Business clusters for BtB journey

    Business clusters for BtB journey BtB Established home Future home Steady Growth New Technology markets markets businesses businesses ▪ India formulations ▪ Brazil ▪ EU ▪ Biosimilars ▪ US oral solids ▪ Mexico ▪ Japan ▪ Transdermals ▪ Emerging markets ▪ Vaccines ▪ Wellness ▪ Injectables ▪ Animal Heal

  7. Slide 7: India formulations

    India formulations Aspirations Market size* : Rs. 660 bn+ Market growth* : 17%  Consolidate and strengthen leadership in key areas – Zydus size** : Rs. 27 bn+ CVS, GI, respiratory, female healthcare Market Share* : 4.2% Zydus growth** : 14%  Continue to be one of the significant contributors to re

  8. Slide 8: US Oral Solids

    US Oral Solids Market size* : >$ 70 bn Aspirations Market growth* : 6-8% Zydus size** : ~ $ 260 mn  Be amongst the top 10 generic cos. in US with Zydus growth** : 23% continued strong focus on customer needs  One of the significant contributors to revenues and profits 50%+ CAGR in Sales (Last 5 ye

  9. Slide 9: Brazil

    Brazil Market size* : >$ 16 bn Aspirations Market growth* : 12-14% Zydus size** : Rs. 2473 mn  To be among top 15 companies in 2015 Zydus growth** : 10% Strengths to be leveraged  Presence in branded generics and generic generics segments  Local manufacturing site  Robust product pipeline from I

  10. Slide 10: Mexico

    Mexico Market size* : >$ 10 bn Aspirations Market growth* : ~9%  Build a profitable business in 2015  40+ product launches and 60 + fillings by 2015 Strengths to be leveraged  Set-up own subsidiary in Mexico to commence operations  Building regulatory pipeline : 17 filings so far  Commercial op

  11. Slide 11: Steady Growth Markets

    Steady Growth Markets Aspirations : To be amongst the leading players in these generics markets EU  9th largest in France, among top 20 in Spain Mkt. Size* : ~$ 5 bn  Expansion through new products : launched 100+ molecules in France (France + Spain Gx) and 55+ molecules in Spain so far (incl. sev

  12. Slide 12: Steady Growth Businesses

    Steady Growth Businesses Wellness Aspirations : Rs. 500 cr. sales by 2013, continue growth momentum  Leadership in sugar substitutes (90% + market share), peel-off and scrub range for skin-care and margarine categories in India Zydus Size **: Rs. 3446 mn  Continuous thrust on category expansion th

  13. Slide 13: Joint Ventures and Partnerships

    Joint Ventures and Partnerships Aspirations : Value creation through win-win alliances and be a partner of choice Zydus Nycomed JV Zydus Hospira JV  State-of-the-art mfg. facility for APIs of  State-of-the-art cytotoxic facility approved Nycomed by leading authorities like MHRA, USFDA,  Commissio

  14. Slide 14: Biosimilars

    Biosimilars Aspirations : Strengths to be leveraged Drive substantial business by 2015  Dedicated facility for product development and mfg. through…  Marketing in India and emerging  170+ experienced scientists markets  Strong pipeline: 17 biosimilars and 2 novel products  Licensing / co-develo

  15. Slide 15: New Technologies

    New Technologies Aspirations : To be a leading market player in complex technologies  State-of-the-art product development and manufacturing facility set-up in SEZ near Ahmedabad Transdermals  2 patches already filed with US FDA  Several other patches under development Mkt. Size* : $ 20 bn  Full

  16. Slide 16: NCE research

    NCE research Aspirations : Add more NCEs in pipeline to drive towards becoming a research based pharma co. by 2020 Key strengths NCE Pipeline  State-of-the art Lead Pre- Drug clinical research facility Project Target Indication optimi- IND Phase I Phase II Phase III NDA Discovery Develop- saiton 

  17. Slide 17: World class infrastructure to support BtB journey

    World class infrastructure to support BtB journey Formulations Mfg. Oral Solids (India) Oral Solids Other dosage forms  Ahmedabad (USFDA ) (outside India) (India)  Baddi (USFDA)  US (Nesher Pharma –  Transdermals – controlled substances) Ahmedabad SEZ  Goa  Brazil  Topicals –  Sikkim Ahmedab

  18. Slide 18: Pillars of Organisational Health

    Pillars of Organisational Health Key initiatives identified to improve overall organisation health in four key areas. Creating value and Promoting Strengthening Enhancing bottom-up developing talent collaboration across accountability by innovation across the across the businesses and proper perform

  19. Slide 19: Key Financial Numbers – Q1 12-13

    Key Financial Numbers – Q1 12-13 Consolidated (Rs. Mio.) Amount Gr.% Segment-wise Gross Sales Total Income from Operations1 15,944 32.7% India Form., PBIDT2 3,514 37.9% 38% PBIDT % to Income from Ops. 22.0% JVs, 8% Profit before tax3 2,779 37.1% APIs, 5% PBT % to Income from Ops. 17.4% Animal Health

  20. Slide 20: Thank You.

    Thank You. Safe Harbour Statement This presentation may include certain “forward looking statements” , based on current expectations, within the meaning of applicable laws and regulations. Actual results may differ and the company does not guarantee realization of these statements. The Company also

Cadila Healthcare — Investor Presentation (September 2012) on 6ix